Australija - anglų - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - linezolid, quantity: 600 mg - tablet - excipient ingredients: croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; ethylcellulose; silicon dioxide; povidone; microcrystalline cellulose; diethyl phthalate; purified talc - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. it has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Airija - anglų - HPRA (Health Products Regulatory Authority)

accord healthcare limited - linezolid (form iii) - film coated tablet - 600 milligram - linezolid - antibacterials for systemic use; other antibacterials - linezolid is indicated in adults for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. in determining whether linezolid is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among gram positive bacteria should be taken into consideration. (see section 5.1 for the appropriate organisms).

Australija - anglų - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; magnesium stearate; maize starch; sodium starch glycollate type a; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - linezolid ca is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid ca is active against gram-positive bacteria only. ,linezolid ca has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; hyprolose; microcrystalline cellulose; maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - linezolid ca is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid ca is active against gram-positive bacteria only. ,linezolid ca has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - linezolid, quantity: 600 mg - injection, solution - excipient ingredients: glucose monohydrate; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - linezolid, quantity: 400 mg - injection, solution - excipient ingredients: glucose monohydrate; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - linezolid, quantity: 200 mg - injection, solution - excipient ingredients: glucose monohydrate; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Airija - anglų - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - linezolid - solution for infusion - 2 milligram(s)/millilitre - other antibacterials; linezolid - antibacterials for systemic use - linezolid clonmel is indicated in adults for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. in determining whether linezolid clonmel is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among gram positive bacteria should be taken into consideration

Airija - anglų - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - linezolid - film-coated tablet - 600 milligram(s) - other antibacterials; linezolid - antibacterials for systemic use, other antibacterials - linezolid krka is indicated in adults for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. in determining whether linezolid krka is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among gram positive bacteria should be taken into consideration

Australija - anglų - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - linezolid, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: sodium citrate; sodium hydroxide; glucose monohydrate; citric acid; hydrochloric acid; water for injections - linezolid is indicated for the treatment of suspected or proven infections due to gram-positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.